วีดีโอ

www.laaocclusion.org Closure and final voting on patient selection and sources of referral, includes the clinical rationale and how to develop the referral channel.

www.laaocclusion.org NOACs have a lower intra-cranial bleeding risk than Vitamine K antagonist. Yet, gastro-intestinal bleeding is higher. Therefore, are patients with recurrent GI-bleeds on NOAC candidate for left atrial appendage occlusion?

www.laaocclusion.org The perspective from a neurologist on referring patients with a prior ischemic stroke on OAC or NOAC; is there a suitable patient population for left atrial appendage occlusion?

www.laaocclusion.org Includes the guidelines for the AF patients and the clinical rationale for combining or staging AF ablation and LAA occlusion therapy.

www.laaocclusion.org Introduction to discussion on patient selection and sources of referral, includes the clinical rationale and how to develop the referral channel.

www.laaocclusion.org What is the role of the patient? Who are the 'right' patients for LAA Occlusion, and is there future perspective for physicians interacting with patients directly requesting this therapy?

www.laaocclusion.org Heart & Brain Summit 2017 Expert Panel discussion on balancing stroke risk & bleeding risk in patients with Atrial Fibrillation. This includes a discussion on trials, knowledge gaps with a main focus on patients with an elevated bleeding risk.

www.laaocclusion.org Heart & Brain Summit 2017 Expert Panel discussion on balancing stroke risk & bleeding risk in patients with Atrial Fibrillation

www.laaocclusion.org Heart & Brain Summit 2017 New oral anticoagulants or NOACs, with favorable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. There are still limitations associated. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for tr...

www.laaocclusion.org Heart & Brain Summit 2017 Broad based review, starting with the basic stroke risk management scores to bleeding risk scores towards expert knowledge and additional diagnostics to help define individual bleeding risk

www.laaocclusion.org Heart & Brain Summit 2017 Contraindications to OAC: Which are the patients who cannot legitimately take anti-coagulants - who have adverse events and where it won't work.

www.laaocclusion.org Heart & Brain Summit 2017 The incidence of ICH has remained unchanged and prevention takes a higher priority, now that more patients are on OAC than before. The management of ICH involves admission to stroke units, BP lowering and reversal of OAC.

www.laaocclusion.org Heart & Brain Summit 2017 The dilemma: should we start, or should we not start anti-coagulation therapy in patients with a prior intracranial hemorrhage and with AF?

www.laaocclusion.org Heart & Brain Summit 2017 There are many things to be learned from PFO trails for stroke prevention in other stroke prevention trials, such as the LAA occlusion trials.